Immunochina logo

Immunochina Pharmaceuticals

Immunochina is a clinical stage biotechnology company, engages in the research and development of chimeric antigen receptor (CAR) T-cell (CAR-T) therapies and a lentiviral vector manufacturing platform for the treatment of malignant tumors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.immunochina.com
Founded2015
Disease Focus
Development Stage
STOCK CODENA
Address
Building 1, B Zone, Yiyuan Cultural and Creative Industry Base, No. 65, Xingshikou Road, Haidian District
Beijing
China
Email
Contact Number
18801159260

In Jan 2019, Immunochina Pharmaceuticals Raised $20.4 Million in Series C Financing led by a syndicate of Chinese and international investors including Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital, and China Resources Innovative Equity Investment Fund.